Neurosense Therapeutics Ltd (NRSN)

Dec 09, 2025

Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight - Yahoo Finance

Dec 09, 2025

Dec 09, 2025

A better buy-in window may exist right now for Lexicon Pharmaceuticals Inc (LXRX) - setenews.com

Dec 09, 2025

Dec 08, 2025

NRSN: PARAGON phase III ALS trial starts mid-2026, with strong data, FDA clearance, and global scope - TradingView

Dec 08, 2025

Dec 08, 2025

NRSN: Global phase III ALS trial set for mid-2026, with strong efficacy and active partnership talks - TradingView

Dec 08, 2025

Dec 08, 2025

NeuroSense Completes Data Collection for Alzheimer’s Trial - TipRanks

Dec 08, 2025

Dec 08, 2025

NeuroSense (NRSN) locks RoAD Phase 2 Alzheimer’s trial database, eyes Q1 2026 data - Stock Titan

Dec 08, 2025

Dec 08, 2025

NeuroSense completes data collection for Alzheimer’s trial - MSN

Dec 08, 2025

Dec 05, 2025

Will NeuroSense Therapeutics Ltd. (H1Z) stock outperform value peersEarnings Summary Report & Daily Oversold Stock Bounce Ideas - Newser

Dec 05, 2025

Dec 05, 2025

How strong is NeuroSense Therapeutics Ltd. Equity Warrant stock balance sheetMarket Performance Report & Verified Short-Term Trading Plans - Newser

Dec 05, 2025

Dec 04, 2025

NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 - Nasdaq

Dec 04, 2025

Dec 04, 2025

NeuroSense Therapeutics LtdResuming regulatory advancement in Canada for PrimeC in amyotrophic lateral sclerosis - marketscreener.com

Dec 04, 2025

Dec 04, 2025

NeuroSense Therapeutics Plans Pre-NDS Meeting with Health Canada for ALS Drug - TipRanks

Dec 04, 2025

Dec 04, 2025

Neurosense Therapeutics LtdResuming Regulatory Advancement In Canada For Primec In Amyotrophic Lateral Sclerosis - TradingView

Dec 04, 2025

Dec 04, 2025

NeuroSense (NASDAQ: NRSN) plans April 2026 Health Canada pre-NDS as it eyes mid-2026 NDS - Stock Titan

Dec 04, 2025

Dec 04, 2025

Is NeuroSense Therapeutics Ltd. stock overvalued by current metricsMarket Growth Review & Capital Protection Trading Alerts - Newser

Dec 04, 2025

Dec 04, 2025

How interest rate cuts could boost NeuroSense Therapeutics Ltd. Equity Warrant stockWeekly Trade Summary & AI Enhanced Trade Execution Alerts - Newser

Dec 04, 2025

Dec 03, 2025

NeuroSense Therapeutics (NRSN) Stock Analysis Report | Financials & Insights - Benzinga

Dec 03, 2025

Dec 02, 2025

What downside risks could hit NeuroSense Therapeutics Ltd. (H1Z) stockPortfolio Value Summary & Risk Managed Investment Signals - Newser

Dec 02, 2025

Dec 01, 2025

Aug EndMonth: How NeuroSense Therapeutics Ltd stock compares to growth peersWeekly Investment Report & Risk Managed Investment Strategies - BỘ NỘI VỤ

Dec 01, 2025

Nov 29, 2025

Is NeuroSense Therapeutics Ltd H1Z a good long term investmentMean Reversion Trades & High Return Capital Strategies - earlytimes.in

Nov 29, 2025

Nov 28, 2025

NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers (PR Newswire) - Aktiellt

Nov 28, 2025

Nov 28, 2025

Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community (PR Newswire) - Aktiellt

Nov 28, 2025

Nov 27, 2025

Hedge Fund Moves: How NeuroSense Therapeutics Ltd. stock compares to growth peers2025 Bull vs Bear & Proven Capital Preservation Methods - moha.gov.vn

Nov 27, 2025

Nov 25, 2025

NeuroSense Therapeutics (NASDAQ:NRSN) Given “Buy” Rating at D. Boral Capital - Defense World

Nov 25, 2025

Nov 25, 2025

NeuroSense Gains FDA Approval for Phase 3 ALS Trial - MSN

Nov 25, 2025

Nov 25, 2025

Prepare Yourself for Liftoff: NeuroSense Therapeutics Ltd (NRSN) - setenews.com

Nov 25, 2025

Nov 24, 2025

D. Boral Capital Maintains NeuroSense Therapeutics (NRSN) Buy Recommendation - Nasdaq

Nov 24, 2025

Nov 24, 2025

NeuroSense receives FDA clearance to initiate pivotal phase 3 trial for PrimeC in ALS - marketscreener.com

Nov 24, 2025

Nov 24, 2025

NeuroSense Therapeutics (NRSN) Maintains 'Buy' Rating and $14 Ta - GuruFocus

Nov 24, 2025

Nov 24, 2025

NeuroSense Therapeutics Cleared by FDA to Initiate Phase 3 Trial for PrimeC to Treat ALS - marketscreener.com

Nov 24, 2025

Nov 24, 2025

NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS - Barchart.com

Nov 24, 2025

Nov 21, 2025

NeuroSense Therapeutics Ltd. (NRSN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Nov 21, 2025

Nov 21, 2025

Can NeuroSense Therapeutics Ltd. (H1Z) stock ride next bull market cyclePortfolio Value Summary & AI Forecasted Stock Moves - newser.com

Nov 21, 2025

Nov 21, 2025

NeuroSense Therapeutics Schedules Shareholder Meeting to Approve Equity Compensation - TipRanks

Nov 21, 2025

Nov 21, 2025

Can NeuroSense Therapeutics Ltd. stock hit analyst price targetsQuarterly Portfolio Summary & Free Real-Time Volume Trigger Notifications - newser.com

Nov 21, 2025

Nov 21, 2025

[6-K] NeuroSense Therapeutics Ltd. Current Report (Foreign Issuer) | NRSN SEC FilingForm 6-K - Stock Titan

Nov 21, 2025

Nov 21, 2025

Is NeuroSense Therapeutics Ltd. (H1Z) stock a safe buy pre earningsWatch List & Consistent Growth Equity Picks - newser.com

Nov 21, 2025

Nov 20, 2025

Will NeuroSense Therapeutics Ltd. (H1Z) stock beat revenue estimatesDip Buying & Free Reliable Trade Execution Plans - newser.com

Nov 20, 2025

Nov 20, 2025

How strong dollar benefits NeuroSense Therapeutics Ltd. (H1Z) stockJuly 2025 Final Week & Expert Approved Trade Ideas - newser.com

Nov 20, 2025

Nov 20, 2025

Using RSI to spot recovery in NeuroSense Therapeutics Ltd.IPO Watch & Weekly Top Stock Performers List - newser.com

Nov 20, 2025

Nov 20, 2025

What risks investors should watch in NeuroSense Therapeutics Ltd. Equity Warrant stockQuarterly Portfolio Review & Low Volatility Stock Suggestions - newser.com

Nov 20, 2025

Nov 19, 2025

Why NeuroSense Therapeutics Ltd. stock is in analyst buy zoneJuly 2025 Retail & Free Safe Entry Trade Signal Reports - newser.com

Nov 19, 2025

Nov 19, 2025

Key metrics from NeuroSense Therapeutics Ltd. Equity Warrant’s quarterly data2025 Geopolitical Influence & Advanced Swing Trade Entry Plans - newser.com

Nov 19, 2025

Nov 19, 2025

What sentiment indicators say about NeuroSense Therapeutics Ltd. stockQuarterly Portfolio Review & High Conviction Trade Alerts - newser.com

Nov 19, 2025

Nov 19, 2025

Is NeuroSense Therapeutics Ltd. stock a bargain at current levels - newser.com

Nov 19, 2025

Nov 19, 2025

Will NeuroSense Therapeutics Ltd. (H1Z) stock sustain uptrend momentumWeekly Earnings Recap & Weekly Return Optimization Alerts - newser.com

Nov 19, 2025

Nov 19, 2025

NeuroSense Bets On Breakthrough ALS And Alzheimer’s Treatments - Finimize

Nov 19, 2025